BRD0705 |
Catalog No.GC39181 |
BRD0705 es un inhibidor de GSK3α potente, selectivo paralog y activo por vÍa oral con una IC50 de 66 nM y una Kd de 4,8 μM. BRD0705 muestra una mayor selectividad para GSK3α (8 veces) frente a GSK3β (IC50 de 515 nM). BRD0705 se puede utilizar para la investigaciÓn de leucemia mieloide aguda (AML).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2056261-41-5
Sample solution is provided at 25 µL, 10mM.
BRD0705 is a potent, paralog selective and orally active GSK3α inhibitor with an IC50 of 66 nM and a Kd of 4.8 μM. BRD0705 displays increased selectivity for GSK3α (8-fold) versus GSK3β (IC50 of 515 nM). BRD0705 can be used to treat acute myeloid leukemia (AML)[1].
[1]. Wagner FF, et al. Exploiting an Asp-Glu "switch" in glycogen synthase kinase 3 to design paralog-selective inhibitors for use in acute myeloid leukemia. Sci Transl Med. 2018 Mar 7;10(431). pii: eaam8460.
Average Rating: 5
(Based on Reviews and 21 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *